Therapeutic antibodies have been developed to prevent or slow the cognitive decline in Alzheimer’s disease (AD) but with limited clinical success to date. These treatment failures suggest that antibodies vary in their therapeutic efficacy and that more effective antibodies or combinations of antibodies need to be identified. To address this issue, researchers at UCI have developed a novel screening platform that can identify antibodies that may prevent or treat AD or other neurodegenerative disorders with high efficacy from human blood.
Roughly 5.4 million people in the US are living with Alzheimer’s Disease (AD). This number is expected to almost triple by 2050 unless new, effective treatments are discovered. To date, immunotherapeutics to prevent or treat AD have yielded limited clinical success for most patients. The main reason for these treatment failures is the amyloid that accumulates in AD is conformationally diverse, and current antibody therapies do not target each specific AD-associated protein form present in the disease condition and therefore vary in their efficacy. The technology is a screening platform that can identify therapeutic antibodies from human blood that are correlated with avoidance of AD. These antibodies have a high selectivity for a vast array of unique AD-associated protein signatures, thus may be more efficacious as single agent or combination diagnostics and immunotherapeutics than those currently available for AD. Using this platform, promising immunotherapeutic candidates have already been discovered. This technology can be applied to identify antibodies associated with other neurodegenerative disorders.
· Can readily identify antibodies directly from human blood that may have higher vaccination efficacy for AD or other neurodegenerative disorders than those currently available to patients
· Quick and accurate identification of antibodies with high specificity for AD-causing proteins
· Approach is applicable to many diseases, and is rapid and inexpensive utilizing serum samples from clinically characterized patients and controls
The technology has been validated with human blood samples derived from healthy individuals and individuals with AD. Over thirty different conformation-dependent monoclonal antibodies were shown to display unique patterns of immunoreactivity. Animal studies will be performed before the submission of an IND application to conduct clinical trials.